Terms: = Head and neck cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Clinical Outcome
4 results:
1. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
2. The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy.
Sun Y; Cheng S; Lu Y; Zheng X; Ye K; Ge H
J Cancer Res Ther; 2016; 12(1):90-5. PubMed ID: 27072217
[TBL] [Abstract] [Full Text] [Related]
3. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract] [Full Text] [Related]
4. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (alk)-negative, anaplastic large-cell lymphoma (ALCL).
Mencía-Gutiérrez E; Gutiérrez-Díaz E; Salamanca J; Martínez-González MA
Int J Dermatol; 2006 Jun; 45(6):766-9. PubMed ID: 16796648
[TBL] [Abstract] [Full Text] [Related]
